UPDATE: Actavis Launches Generic Version of Intuniv

Actavis plc

today announced that it has launched a generic version of Intuniv(R) (guanfacine hydrochloride), as part of a settlement agreement with Shire plc. Actavis has begun shipping the product and, under applicable Hatch Waxman rules, is entitled to 180 days of marketing exclusivity. Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO Intuniv(R) is a prescription medicine used to treat Attention Deficit Hyperactivity Disorder in patients ages 6 to 17. For the 12-month period ending June 30, 2014, Intuniv(R) had U.S. sales of approximately $668 million, according to IMS Health data. About Actavis Actavis plc

, headquartered in Dublin, Ireland, is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world. Actavis markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women's health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. The company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.